

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **UPDATED INFORMATION OF THE GROUP'S PRODUCT TUL01101 OINTMENT**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the applications for clinical trial of class-1 new drug TUL01101 Ointment (Specifications: 0.5%, 1%, 2%) applied by Zhuhai United Laboratories Co., Ltd., a wholly-owned subsidiary of the Company, have been approved by China National Medical Products Administration, with reference numbers of CXHL2200542, CXHL2200543 and CXHL2200544.

TUL01101 Ointment is a topical preparation of Janus Kinase (JAK) inhibitor for the treatment of mild to moderate atopic dermatitis with proven efficacy and fewer side effects. JAK inhibitor drugs include oral preparations and topical skin preparations. Compared with the oral preparation, JAK inhibitor topical preparation can achieve high retention of the drug in the skin, while reducing the systemic absorption of the drug, resulting in high efficacy and less adverse reactions, thus enhancing the safety. To date, only a few topical JAK inhibitor preparations have been approved for marketing in overseas markets, and no such product has been approved in China market.

The product is expected to provide a new and safer treatment choice for atopic dermatitis patients. In the future, the Company will continue to devote itself to the research and development of new products, which are expected to create more benefits for the Company and its shareholders.

By Order of the Board

**The United Laboratories International Holdings Limited**

**Tsoi Hoi Shan**

*Chairman*

Hong Kong, 26 October 2022

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.